X4 Pharmaceuticals Inc (NASDAQ:XFOR) has earned an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. X4 Pharmaceuticals’ rating score has improved by 50% in the last three months as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1 year consensus price objective of $22.00 for the company and are expecting that the company will post ($0.79) earnings per share for the current quarter, according to Zacks. Zacks has also assigned X4 Pharmaceuticals an industry rank of 77 out of 256 based on the ratings given to related companies.
A number of research analysts have recently weighed in on the company. Cowen assumed coverage on X4 Pharmaceuticals in a research report on Wednesday, June 5th. They set an “outperform” rating for the company. Canaccord Genuity assumed coverage on X4 Pharmaceuticals in a research report on Tuesday, May 21st. They set a “buy” rating and a $27.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on X4 Pharmaceuticals in a research report on Friday, June 7th. They set a “buy” rating and a $27.00 price objective for the company.
X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($6.67) earnings per share for the quarter.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.